Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomised, open label, parallel group, multi-centre, phase II study of progression free survival comparing ZD1839 (IRESSA) (250 mg tablet) versus vinorelbine (30 mg/mexp2) infusion in chemonaive, elderly patients with locally advanced (stage IIIB) or metastatic (stage IV) NSCLC [non-small cell lung cancer]

Next Previous
X
Search
Trial Profile

A randomised, open label, parallel group, multi-centre, phase II study of progression free survival comparing ZD1839 (IRESSA) (250 mg tablet) versus vinorelbine (30 mg/mexp2) infusion in chemonaive, elderly patients with locally advanced (stage IIIB) or metastatic (stage IV) NSCLC [non-small cell lung cancer]

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 10 Sep 2008

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gefitinib (Primary) ; Vinorelbine
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms INVITE
  • Sponsors AstraZeneca

    • Most Recent Events

    • 10 Sep 2008 Primary endpoint 'Progression free survival' has not been met.
    • 10 Sep 2008 Results reported in the Journal of Clinical Oncology.
    • 17 Oct 2007 Status changed from in progress to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top